Mutations in the Nonstructural Protein 3A Confer Resistance to the Novel Enterovirus Replication Inhibitor TTP-8307

Armando M. De Palma, Hendrik Jan Thibaut, Lonneke van der Linden, Kjerstin Lanke, Ward Heggermont, Stephen Ireland, Robert Andrews, Murty Arimilli, Taleb H. Al-Tel, Erik De Clercq, Frank van Kuppeveld and Johan Neyts

Published Ahead of Print 23 February 2009.

Updated information and services can be found at:
http://aac.asm.org/content/53/5/1850

These include:

REFERENCES
This article cites 49 articles, 34 of which can be accessed free at: http://aac.asm.org/content/53/5/1850#ref-list-1

CONTENT ALERTS
Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more»
Mutations in the Nonstructural Protein 3A Confer Resistance to the Novel Enterovirus Replication Inhibitor TTP-8307

Armando M. De Palma,1 Hendrik Jan Thibaut,1† Loneke van der Linden,2† Kjerstin Lanke,2 Ward Heggermont,1 Stephen Ireland,3 Robert Andrews,3 Murty Arimilli,3 Taleb H. Al-Tel,3 Erik De Clercq,1 Frank van Kuppeveld,2 and Johan Neyts1*

Rega Institute for Medical Research, University of Leuven, B-3000 Leuven, Belgium; Department of Medical Microbiology, Radboud University Nijmegen, Nijmegen Centre for Molecular Life Sciences, 6500 HB Nijmegen, The Netherlands; and Transtech Pharma, Inc., 4170 Mendenhall Oaks Parkway, High Point, North Carolina 27265

Received 15 July 2008/Returned for modification 19 September 2008/Accepted 19 January 2009

A novel compound, TTP-8307, was identified as a potent inhibitor of the replication of several rhinovirus and enteroviruses. TTP-8307 inhibits viral RNA synthesis in a dose-dependent manner, without affecting polypeptide synthesis and/or processing. Drug-resistant variants of coxsackievirus B3 were all shown to carry at least one amino acid mutation in the nonstructural protein 3A. In particular, three mutations located in a non-structured region preceding the hydrophobic domain (V45A, I54F, and H57Y) appeared to contribute to the drug-resistant phenotype. This region has previously been identified as a hot spot for mutations that resulted in resistance to enviroxime, the sole 3A-targeting enterovirus inhibitor reported thus far. This was corroborated by the fact that TTP-8307 and enviroxime proved cross-resistant. It is hypothesized that TTP-8307 and enviroxime disrupt proper interactions of 3A(B) with other viral or cellular proteins that are required for efficient replication.

Enteroviruses comprise several pathogens that are implicated in a large variety of clinical manifestations that range from mild illnesses to more serious or even life-threatening diseases, such as meningitis, encephalitis, myocarditis, pancreatitis, acute paralysis, or neonatal sepsis (30, 40). Enteroviruses are small, nonenveloped, and spherical in shape, with a diameter of about 30 nm. The icosahedrally shaped capsids are assembled from 60 protomers, each composed of four structural proteins, designated VP1 (for viral protein 1), VP2, VP3, and VP4 (38, 39). The enteroviral genome consists of a single-stranded, positive-sense RNA of approximately 7,500 bases in length. The coding region of the viral genome is divided into three primary precursor molecules which contain the four structural (derived from P1) and 10 nonstructural viral proteins (derived from P2 and P3).

The nonstructural protein 3A and its precursor 3AB are derived from P3 and are indispensable for viral replication. A feature of 3A that has been the subject of many studies is its ability to serve as a membrane anchor through the presence of a 22-residue hydrophobic domain that forms an amphipathic helix near its C terminus (25). In infected cells, both 3A and 3AB are found in association with membranes (17). In the context of the viral replication complex, 3AB serves to deliver the basic protein VPg (3B) at the 5’ end of the RNA strand during replication (18, 41), and, hence, to recruit the other proteins of the replication complex to the cellular membranes, the site of viral replication. The 3B protein then serves as a primer for the initiation of RNA synthesis, probably only after it has been cleaved from the 3A portion and not when it is still in the 3AB membrane-bound state (17). Cleavage of 3A is mediated by 3Cpro/3CDpro and can only occur when the protein is membrane bound (26). Moreover, this proteolysis was shown to be enhanced in the presence of purified 3AB but not 3A (26, 31, 49). Stimulation of catalytic activity by 3AB has also been observed for the 3Dpol, both when 3AB is membrane bound and purified, and this has been suggested to occur via stabilization of the primer-template/3Dpol complex (26, 28, 35–37). 3AB but not 3A shows nonspecific RNA-binding activity but binds specifically to the 5’ RNA cloverleaf of the viral RNA genome when it is complexed with 3Dpol (20, 28, 48). The protein also binds to the 3’ untranslated region but, in contrast to binding at the 5’ cloverleaf, binding at the 3’ untranslated region can also occur in the absence of other proteins (20). Moreover, 3AB has been shown to induce membrane permeability in bacterial but not mammalian cells (1, 24, 25, 29), to induce membrane alterations in the endoplasmic reticulum (ER) (15), to form homodimers (26, 42, 47), and to be involved in host range pathogenicity (2, 27, 33, 34).

Apart from these features that are directly or indirectly associated with viral replication, 3A and 3AB are also involved in processes that specifically affect the host cell. It is well documented that protein 3A is able to interfere with cellular protein secretion via inhibition of ER-to-Golgi transport, causing accumulation of proteins otherwise destined for export (4, 13, 14). Determinants for this feature are located at the N terminus (4, 13, 44–46). This inhibition of ER-to-Golgi transport has been shown to reduce or inhibit the secretion of antiviral cytokines such as interleukin-6, interleukin-8, and beta interferon (12), the concentration of tumor necrosis factor receptor on the surfaces of infected cells (32), and the presen-

* Corresponding author. Mailing address: Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium. Phone: 32(0)16-33-73-53. Fax: 32(0)16-33-73-40. E-mail: johan.neyts@rega.kuleuven.be.
† These two authors made equal contributions.
Published ahead of print on 23 February 2009.
tation of antigen in the context of major histocompatibility complex class I molecules (7). In doing so, ER-to-Golgi transport inhibition in infected cells might help in evading the host cell’s immune response and, hence, promote viral replication in an indirect way, although this inhibition is not required for efficient viral replication per se (12, 13).

The indispensable presence of 3A(B) during viral replication makes this protein an attractive candidate as a target for inhibition of viral replication. Thus far, only one compound (enviroxime) has been reported to target protein 3A (8, 22, 23). Despite its potent antiviral activity, however, the development of this compound was halted, mainly because of toxicity and an unfavorable pharmacokinetic profile (6). We here report on a novel compound (TTP-8307) that was identified in a screening campaign for inhibitors of the replication of enteroviruses. The compound appeared to be a potent inhibitor of the replication of several rhino- and enteroviruses.

MATERIALS AND METHODS

Cells and viruses. Vero cells (ATCC CCL-81), Buffalo green monkey (BGM) cells (ECACC 90092601), and HeLa cells (ATCC CCL-2) were grown in minimal essential medium (Gibco, Mellebeek, Belgium) supplemented with 10% heat-inactivated fetal bovine serum (Integro, Leuvenheim, The Netherlands), 5% bicarbonate (Gibco), and 5% l-glutamine (Gibco). Cells were grown at 37°C in a 5% CO2 incubator. Coxsackievirus B3 (CVB3) was derived from plasmid pCB53/T7, which contains a full-length cDNA of CVB3 strain Nancy behind a T7 RNA promoter (45). For assays involving virus growth, 2% fetal bovine serum was used instead of 10% fetal bovine serum. Rhinoviruses were provided by K. Andries, and the poliovirus Sabin 1, 2, and 3 strains were from B. Rombaut (Vrije Universiteit Brussel, Brussels, Belgium). Enterovirus 71 (BrCy) and coxsackieviruses A16 (G-10) and A21 (Coe) were obtained from the Rijksinstituut voor Volksgezondheid en Milieu (The Netherlands).

Compounds. The synthesis of TTP-8307 (436 g/mol) will be reported elsewhere. The purity of the compound used in the present study was determined to be >90% by spectroscopic (nuclear magnetic resonance) and chromatographic (liquid chromatography-mass spectrometry) techniques. TBZ-E-029 and enviroxime were synthesized as reported elsewhere (10). Guanidine hydrochloride was from Sigma (Bornem, Belgium). All compounds were solubilized in dimethyl sulfoxide at 20 mM and stored at 4°C. For working solutions, the dimethyl sulfoxide stocks were diluted in minimal essential medium to the desired concentration.

In vitro RNA transcription and transfection. Prior to in vitro RNA transcription, plasmid p53CB3/T7 was linearized with SalI (Promega, Leiden, The Netherlands) and viral RNA was quantified by means of real-time qRT-PCR. The levels of viral RNA in the supernatant, as well as intracellular RNA of the infected cultures, was collected, subjected to plaque purification (in the presence of 20 μM TTP-8307), and used as described elsewhere (9). Each reaction was performed with 25 ng of plasmid DNA in the presence or absence of 25 μM TTP-8307. The PCR consisted of an RT step (30 min at 48°C), a Taq activation step (10 min at 95°C), and 50 cycles of denaturation (15 s at 94°C) and annealing/extension (30 s at 60°C). The PCR copy number in each sample was determined by a standard curve generated from increasing copy numbers of a synthetic transcript corresponding to 67 nucleotides of the CVB3 genome.

Time of drug addition studies. Vero cells, grown to confluence in 24-well culture plates, were infected with 104 50% cell culture infective doses (CCID50) of coxsackievirus B3. After an adsorption period of 1 h at 37°C, virus was removed and replaced with 500 μl of growth medium. At 1-h intervals, 500 μl of medium containing a 2× compound solution was added (final concentration, 25 μM). At 8 h postinfection, the supernatant, as well as intracellular RNA of infected and viral RNA was quantified by means of real-time qRT-PCR. The levels of viral RNA were compared to their untreated controls.

Analysis of viral protein processing in vivo. BGM cells, grown to confluence in 24-well culture plates, were infected with coxsackievirus B3 at a multiplicity of infection of 50. At 5 h postinfection, the medium was replaced with 300 μl of methionine-free medium. Thirty minutes later, the cultures were pulse-labeled in methionine-free medium containing 1 μl of Met35S (SP) well in the absence or presence of TTP-8307 (25 μM final concentration) for 30 min. At 6 h postinfection cells were washed once with PBS and lysed in 75 μl of cold lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, and 0.05% sodium deoxycholate (SDS). Translation products were analyzed on a 12.5% polyacrylamide gel containing SDS. The gels were fixed in 30% methanol-10% acetic acid, rinsed in dimethyl sulfoxide, fluorographed with 20% 2,5-diphenyloxazole in dimethyl sulfoxide, dried, and exposed to Kodak XAR film.

Generation of TTP-8307-resistant coxsackievirus. Drug-resistant virus was generated by growing virus in the presence of gradually increasing concentrations of TTP-8307 on confluent Vero cultures in 48-well culture plates. After 4 to 5 days of culture, culture supernatant was collected from cultures that exhibited full CPE in the presence of the highest concentration of compound used. This virus was used for a successive round of infection, a procedure that was repeated until full CPE was noticed at concentrations of TTP-8307 (20 μM) that did not allow replication of wild-type virus. Subsequently, the resistant virus pool was subjected to plaque purification (in the presence of 20 μM compound), and individual clones were used for sequencing.
Site-directed mutagenesis. Four mutant CVB3 clones were constructed, containing single amino acid replacements at positions 8, 45, 54, and 57 in protein 3A. The four clones were designated mutant 1 (3A8T), mutant 2 (3A45V), mutant 3 (3A54A), and mutant 4 (3A57V). The corresponding synthetic oligonucleotides (and their complementary reverse oligonucleotides) were used for site-directed mutagenesis: (i) 5′-GGA CCA CCA GTA TAC AGA GAG ACC AAA ATT AGC GTT GCA CC-3′, (ii) 5′-GAA AAA GGA TGG TTG GCT CCT GAG ATC AAC TCC ACC C-3′, (iii) 5′-C TCC ACC CTC CAA TTT GAG AAA CAT GTC AGT CCG G-3′, and (iv) 5′-CC CTC ACC CAA ATT GAG AAA TAT GTC AGT CCG GCT TTC-3′. The mutated sequences are underlined. Site-directed mutagenesis was performed with plasmid pCB53/T7 using the XL-Blue large site-directed mutagenesis kit (Stratagene, Amsterdam, The Netherlands), according to the manufacturer’s instructions. After mutagenesis, the individual clones were verified by sequencing. Next, a 711-bp fragment containing single amino acid replacements at positions 8, 45, 54, and 57 in protein 3A. The four mutant CVB3 clones were designated mutant 1 (3A8T), mutant 2 (3A45V), mutant 3 (3A54A), and mutant 4 (3A57V). The corresponding synthetic oligonucleotides (and their complementary reverse oligonucleotides) were used for site-directed mutagenesis: (i) 5′-GGA CCA CCA GTA TAC AGA GAG ACC AAA ATT AGC GTT GCA CC-3′, (ii) 5′-GAA AAA GGA TGG TTG GCT CCT GAG ATC AAC TCC ACC C-3′, (iii) 5′-C TCC ACC CTC CAA TTT GAG AAA CAT GTC AGT CCG G-3′, and (iv) 5′-CC CTC ACC CAA ATT GAG AAA TAT GTC AGT CCG GCT TTC-3′. The mutated sequences are underlined. Site-directed mutagenesis was performed with plasmid pCB53/T7 using the XL-Blue large site-directed mutagenesis kit (Stratagene, Amsterdam, The Netherlands), according to the manufacturer’s instructions. After mutagenesis, the individual clones were verified by sequencing. Next, a 711-bp fragment containing the desired mutations was isolated using the enzymes BssHII and XL-Blue large site-directed mutagenesis kit (Stratagene, Amsterdam, The Netherlands), according to the manufacturer’s instructions. After mutagenesis, the individual clones were verified by sequencing. Next, a 711-bp fragment containing the desired mutations was isolated using the enzymes BssHII and XL-Blue large site-directed mutagenesis kit (Stratagene, Amsterdam, The Netherlands), according to the manufacturer’s instructions. After mutagenesis, the individual clones were verified by sequencing. Next, a 711-bp fragment containing the desired mutations was isolated using the enzymes BssHII and XL-Blue large site-directed mutagenesis kit (Stratagene, Amsterdam, The Netherlands), according to the manufacturer’s instructions. After mutagenesis, the individual clones were verified by sequencing. Next, a 711-bp fragment containing the desired mutations was isolated using the enzymes BssHII and XL-Blue large site-directed mutagenesis kit (Stratagene, Amsterdam, The Netherlands), according to the manufacturer’s instructions. After mutagenesis, the individual clones were verified by sequencing. Next, a 711-bp fragment containing the desired mutations was isolated using the enzymes BssHII and XL-Blue large site-directed mutagenesis kit (Stratagene, Amsterdam, The Netherlands), according to the manufacturer’s instructions. After mutagenesis, the individual clones were verified by sequencing. Next, a 711-bp fragment containing the desired mutations was isolated using the enzymes BssHII and XL-Blue large site-directed mutagenesis kit (Stratagene, Amsterdam, The Netherlands), according to the manufacturer’s instructions. After mutagenesis, the individual clones were verified by sequencing. Next, a 711-bp fragment containing the desired mutations was isolated using the enzymes BssHII and XL-Blue large site-directed mutagenesis kit (Stratagene, Amsterdam, The Netherlands), according to the manufacturer’s instructions. After mutagenesis, the individual clones were verified by sequencing. Next, a 711-bp fragment containing the desired mutations was isolated using the enzymes BssHII and XL-Blue large site-directed mutagenesis kit (Stratagene, Amsterdam, The Netherlands), according to the manufacturer’s instructions. After mutagenesis, the individual clones were verified by sequencing.

RESULTS

TTP-8307 inhibits replication of several enteroviruses. TTP-8307 was identified in a screening campaign as a selective inhibitor of CVB3 replication in Vero cells. The effect of TTP-8307 (Fig. 1A) was next evaluated against a selection of enteroviruses and rhinoviruses in an MTS-based CPE reduction assay. TTP-8307 inhibits the replication of coxsackievirus B3 and the three poliovirus Sabin strains, as well as coxsackieviruses A16 and A21 (Table 1). TTP-8307 inhibits human rhinoviruses (HRVs) 2, 29, 39, 45, 63, and 85, but not other rhinovirus serotypes (HRV serotypes 9, 14, 15, 41, 42, 70, 72, 86, and 89) or enterovirus 71. Coxsackievirus B3 (CVB3), the prototype of the non-polio enteroviruses, was used to further study the particular characteristics of the antiviral activity of TTP-8307. TTP-8307 inhibited CVB3 replication in a dose-dependent manner (Fig. 2) when monitored either by (i) CVB3-induced CPE formation (Fig. 2A) or (ii) CVB3-induced plaque formation (Fig. 2B).

TTP-8307 acts at a stage that coincides with CVB3 viral RNA replication and polyprotein synthesis/processing. Time of drug addition studies were carried out to obtain a first indication about the stage in the viral replication cycle where TTP-8307 exerts its antiviral activity. Maximal inhibition of viral replication was maintained when the drug was added within the first 3 h postinfection (Fig. 3A). The addition of the drug at a time point later than 3 h postinfection, which coincides with the onset of viral RNA synthesis, resulted in a gradual decrease in antiviral activity. It can thus be concluded that TTP-8307 does not hamper early (attachment, entry, and uncoating) or late (assembly and release) events but rather interferes with intermediate processes, such as viral RNA replication, viral polyprotein synthesis, and/or processing.

TTP-8307 inhibits accumulation of CVB3 viral RNA. The accumulation of viral RNA in the absence or presence of TTP-8307 was monitored upon transfection of BGM cells with an infectious subgenomic replicon of CVB3 (in which the P1 region was replaced with a luciferase marker). Transfection in the presence of TTP-8307 (25 μM) led to a complete inhibition of viral RNA accumulation, whereas an increase in luciferase activity was measured in the absence of compound (Fig. 3B). The replication inhibitor guanidine hydrochloride (2 mM) was included as a reference compound and resulted in the inhibition of viral RNA accumulation as well.

TTP-8307 does not affect CVB3 polyprotein synthesis or processing. Viral protein synthesis and polyprotein processing were monitored in a pulse-labeling experiment in the presence (25 μM) or absence of TTP-8307. From Fig. 3C it is evident that the addition of TTP-8307 at 3 h posttransfection resulted in a gradual decrease in the accumulation of viral RNA, whereas an increase in luciferase activity was measured when the drug was added 6 h posttransfection, indicating that TTP-8307 affects polyprotein synthesis and processing.

<table>
<thead>
<tr>
<th>Virus</th>
<th>Mean EC_{50} (μM) ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TTP-8307</td>
</tr>
<tr>
<td>Human enterovirus A</td>
<td></td>
</tr>
<tr>
<td>CVA16 (G-10)</td>
<td>0.85 ± 0.08</td>
</tr>
<tr>
<td>EV71 (BrCr)</td>
<td>&gt;60</td>
</tr>
<tr>
<td>Human enterovirus B</td>
<td></td>
</tr>
<tr>
<td>CVB3 (Nancy)</td>
<td>1.2 ± 0.1</td>
</tr>
<tr>
<td>Human enterovirus C</td>
<td></td>
</tr>
<tr>
<td>CVA21 (Coe)</td>
<td>5.34 ± 0.93</td>
</tr>
<tr>
<td>Polioviruses</td>
<td></td>
</tr>
<tr>
<td>PV1 (Sabin)</td>
<td>0.51 ± 0.05</td>
</tr>
<tr>
<td>PV2 (Sabin)</td>
<td>0.58 ± 0.05</td>
</tr>
<tr>
<td>PV3 (Sabin)</td>
<td>0.27 ± 0.23</td>
</tr>
<tr>
<td>Major group rhinoviruses</td>
<td></td>
</tr>
<tr>
<td>HRV9</td>
<td>&gt;50</td>
</tr>
<tr>
<td>HRV14</td>
<td>&gt;50</td>
</tr>
<tr>
<td>HRV15</td>
<td>&gt;50</td>
</tr>
<tr>
<td>HRV39</td>
<td>0.65 ± 0.51</td>
</tr>
<tr>
<td>HRV41</td>
<td>&gt;50</td>
</tr>
<tr>
<td>HRV42</td>
<td>&gt;50</td>
</tr>
<tr>
<td>HRV45</td>
<td>0.99 ± 0.04</td>
</tr>
<tr>
<td>HRV63</td>
<td>0.091 ± 0.054</td>
</tr>
<tr>
<td>HRV70</td>
<td>&gt;50</td>
</tr>
<tr>
<td>HRV72</td>
<td>&gt;50</td>
</tr>
<tr>
<td>HRV85</td>
<td>1.22 ± 0.21</td>
</tr>
<tr>
<td>HRV86</td>
<td>&gt;50</td>
</tr>
<tr>
<td>HRV89</td>
<td>&gt;50</td>
</tr>
<tr>
<td>Minor group rhinoviruses</td>
<td></td>
</tr>
<tr>
<td>HRV2</td>
<td>0.80 ± 0.12</td>
</tr>
<tr>
<td>HRV29</td>
<td>0.77 ± 0.38</td>
</tr>
</tbody>
</table>

*Data are mean values for at least three independent experiments. The cytotoxicity of TTP-8307 was determined on confluent Vero and HeLa cells, and the EC_{50} values (i.e., the 50% cytotoxic concentration) were >100 μM. The compound solubility limit in assay medium is 100 μM.*
that a similar pattern of viral proteins was observed in the presence or absence of TTP-8307. Thus, neither the rate of protein synthesis nor the processing of viral proteins was affected by the compound. This observation, together with the observed effect of TTP-8307 in the subgenomic replicon, points to the synthesis of viral RNA as the potential target of action of TTP-8307.

**TTP-8307 resistant CVB3 clones share mutations in the nonstructural protein 3A.** To identify the molecular target of TTP-8307, drug-resistant CVB3 variants were selected. To this end, CVB3 was cultured successively in the presence of increasing concentrations of TTP-8307. After 10 passages, five independently cultured pools of CVB3 were obtained that replicated efficiently in the presence of TTP-8307 at concentrations that exceeded the EC₅₀ more than 10-fold. The virus pools thus obtained were plaque purified in the presence of 20 µM TTP-8307 and one or several clones from each pool were picked up. As such, 10 clones were selected for genotyping (Table 2). Except for clone 1A, all clones carried mutations in two or more different proteins, including 2A, 2B, 2C, 3A, and/or 3D. A remarkable observation, however, was that all clones carried at least one mutation in protein 3A. Furthermore, each of the following four mutations in 3A recurred in different clones (either or not if they derived from the same pool): I8T, V45A, V54A, and H57Y. In contrast, none of the mutations observed in the other proteins occurred more than once in clones that were derived from independently cultured pools. Moreover, three of the four identified mutations in 3A were located in a region that was previously shown to accumulate mutations involved in resistance to the 3A inhibitor enviroxime (see Discussion). The contribution of the 3A mutations to the drug-resistant phenotype was therefore studied in more detail.

**Recombinant CVB3 3A mutants have plaque phenotypes similar to those of wild-type virus.** A plasmid (pCB53/T7) encoding an infectious full-length CVB3 genome was used to generate four recombinant clones carrying the four identified mutations in protein 3A individually. These clones were designated mutant 1 (3A[I8T]), mutant 2 (3A[V45A]), mutant 3 (3A[V54A]), and mutant 4 (3A[H57Y]). Plaque assays with the mutant viruses revealed that infection with these mutant viruses do not result in altered plaque phenotypes compared to wild-type CVB3 (Fig. 4).

**Recombinant CVB3 clones carrying mutations in 3A are resistant to inhibition by TTP-8307 and enviroxime.** Next, the four recombinant mutant viruses were evaluated for their ability to form plaques in the presence of various concentrations of TTP-8307. Two reference molecules were included as a control: enviroxime (previously reported to inhibit enterovirus replication by targeting 3A) and the 2C inhibitor TBZE-029 (9). The graphs depicted in Fig. 5 represent PFU after infection of Vero cells with wild-type virus or the constructed 3A mutants at a given concentration for a given compound. In the absence of drug, all clones (as well as the wild type) resulted in the formation of, on average, $10^4$ to $15 \times 10^4$ plaques per ml. TTP-8307 at a concentration of 8 µM or higher completely prevented the formation of plaques in virus-infected cultures, whereas the recombinant mutant clones were still able to form plaques in the presence of TTP-8307 at these concentrations. In particular, mutants 2 and 3 (and to a lesser extent mutant 4) carrying amino acid mutations V45A and V54F (and H57Y) were still able to generate progeny virus at higher drug concentrations. Mutant 1 (I8T) remained relatively sensitive to inhibition by TTP-8307. A comparable pattern of (lack of) sensitivity of the variant mutants was observed for enviroxime. Enviroxime- and TTP-8307-resistant mutants can thus be considered cross-resistant. Finally, the sensitivity of the different recombinant viruses was assessed in the presence of TBZE-029, a compound that we recently reported to target the nonstructural protein 2C. As expected, TBZE-029 was equipotent in its inhibition of wild-type and mutant viruses. Taken together, these data indicate that in particular 3A mutations V45A, I54F, and H57Y confer resistance to TTP-8307.

**DISCUSSION**

We identified a novel compound, TTP-8307, that potently inhibits the replication of several enteroviruses, including coxsackievirus B3 and poliovirus by interfering with the synthesis of viral RNA. Contemplating the need for antivirals in the end stages of the worldwide polio eradication (5, 11), TTP-8307 might be considered as an interesting compound for lead op-
To determine the viral target of TTP-8307, resistant CVB3 variants were selected. Each clone carried at least one of the following mutations in protein 3A: I8T, V45A, I54F, or H57Y. These mutations were reintroduced in an infectious CVB3 full-length clone and the antiviral sensitivity of the resulting viruses was studied. Mutants 2, 3, and 4 (carrying 3A mutations V45A, I54F, or H57Y) were shown to form plaques in the presence of concentrations of TTP-8307 that did not allow replication of wild-type virus, confirming that these mutations contribute to the observed resistance phenotype. The calculated EC90 values of TTP-8307 for inhibition of these mutant viruses were ca. 8- to 10-fold higher than for wild-type CVB3. Moreover, cross-resistance was observed with enviroxime. The specificity of this resistance profile was corroborated by the fact that a 2C-targeting compound (9, 10) inhibited the replication of the mutants as efficiently as that of the wild-type virus. Mutant I8T allowed for some very low replication in the presence of TTP-8307 and enviroxime. The viruses carrying the engineered mutations proved phenotypically (formation of plaques) comparable to the wild-type virus, suggesting no deleterious effects of the 3A mutations on viral replication. It should be noted, however, that the reconstructed mutants carrying single amino acid mutations in 3A did not exhibit the same high degree of resistance that we observed with the naturally selected clones. In fact, all naturally selected clones
were selected and plaque purified in the presence of 20 μM TTP-8307 and, hence, had EC90 values of > 20 μM. None of the reconstructed viruses carrying single amino acid mutations, however, reached EC90 values of = 20 μM. It may therefore be assumed that other sequence variations (in proteins different than 3A) may contribute to a further increase in the level of resistance to TTP-8307.

An amino acid sequence alignment of the 3A proteins of CVB3, PV1, HRV2, and HRV14 is depicted in Fig. 6. Globally, two major regions were reported to be important for resistance to enviroxime (3, 22, 23). The first region involves residues in the hydrophobic domain of 3A, located near its C terminus, whereas the second region is located between amino acids 40 and 60. This latter region, preceding the hydrophobic domain (underlined in green in Fig. 6), has been predicted to be unstructured, based on the nuclear magnetic resonance structure of the soluble domain of PV protein 3A (42). Remarkably, the 3A mutations that we identified in the present study as major determinants for resistance to TTP-8307 (V45A, I54F, and H57Y) were also located in this region (arrows in Fig. 6A; residues highlighted in Fig. 6C). Moreover, the very same H57Y mutation that was identified in TTP-8307-resistant CVB3 was also detected in enviroxime-resistant CVB3. In contrast to enviroxime, no mutations were detected in the hydrophobic domain of 3A in TTP-8307-resistant CVB3. This may be explained by the fact that TTP-8307 and enviroxime interact with the same region of 3A but that, given their different chemical structure, the precise molecular interactions with the various amino acids in this region may be (partially) different. Single amino acid mutations in the nonstructured region (amino acids 40 to 60) were shown to be sufficient to confer a certain degree of resistance to enviroxime (22, 23), corroborating our present observations. Florez de Sessions et al. observed that a chimeric CVB3 carrying an HRV2 internal ribosome entry site and that was adapted for growth in a neuroblastoma cell line carried the mutation V45A in 3A (16). Similar observations were described by Harris and Racaniello (19), who identified mutations in 3A at amino acid positions that correspond to CVB3 residues 42 and 44 in HRV39 that was adapted for growth in mouse cells. None of these mutations substantially affected viral plaque formation (16, 19), which is in line with our observations. The unstructured region preceding the hydrophobic domain may thus allow for adaptation of the virus to selective pressure of different kinds (e.g., antivirals or a changing host) without compromising viral growth.

A question that remains to be answered is what determines the spectrum of activity of TTP-8307. An alignment of the 3A amino acid sequence of TTP-8307-sensitive and -resistant viruses did not reveal any particular amino acids or regions in 3A that determined whether or not a virus would be inhibited by TTP-8307 (data not shown). For example, CVA16 and entero-
virus 71 (TTP-8307 sensitive and resistant, respectively) share
the N-terminal 3A amino acid sequence entirely, despite their
difference in sensitivity. A possible explanation might be that
3A is a key protein in the replication inhibition, but that pro-
tein other than 3A are involved in this inhibition as well.

Therefore, despite the fact that 3A was identified as a prime
target for TTP-8307 as well as for enviroxime, the precise
mechanism of action for inhibition of viral inhibition by these
compounds remains to be elucidated. In contrast to 2CATPase,
3C(D)pro, and 3Dpol, protein 3A is not thought to be associated
with any enzymatic activity and, hence, the inhibition of this
protein by a compound cannot be assessed in a simple in vitro
enzymatic assay. Rather than hampering a catalytic reaction,
3A-targeting drugs are likely to mediate hindrance of certain
interactions of 3A with other (viral or cellular) proteins in the
viral replication complex, an idea than can be supported given
the multitude of interactions that have been ascribed to this
protein (43, 50). For enviroxime, it was recognized that repli-
cation inhibition is probably not only occurring through tar-
geting of 3A but may also depend on interactions with other
proteins in the replication complex (3). More precisely, a
HRV14 mutant was identified that carried, in addition to 3A
mutations, mutations in 3Dpol. These additional mutations re-
sulted in a higher degree of resistance. These findings are in
line with our observations that several of the identified mutants
carry amino acid changes in proteins other than 3A (Table 2).
However, these mutations were identified in various proteins
(2A, 2B, 2C, and 3D) and at different residue positions. Based
on the hypothesis that TTP-8307 and enviroxime interfere with
3A through inhibition of certain interactions with other pro-
teins, one could postulate that mutations in 3A are necessary
for resistance, but that the level of resistance is increased by
additional mutations in other proteins (that interact with 3A).
Interestingly, recently CVB3 was selected that was resistant to
amiloride; resistance was shown to map to the 3Dpol, but the
resistant variant carried also a mutation at 3A residue I54
(similar to clones 4 and 6 identified in the present study) (21).
The contribution of this 3A mutation to the resistant pheno-
type was however, not further determined.

In conclusion, we identified a novel enterovirus replication
inhibitor that targets the nonstructural protein 3A. Mutations
conferring the highest levels of resistance mapped to the non-
structured region preceding the hydrophobic domain, a region
that was also reported to contain mutations in enviroxime-
resistant viruses. The precise mechanism of viral inhibition by
targeting 3A remains to be addressed in future studies.

ACKNOWLEDGMENTS

This study was supported by the VIZZIER integrated project (LSHG-
CT-2004-511960) from the European Union 6th PCRDT. A.M.D.P. is
a postdoctoral fellow of the FWO-Vlaanderen.

We thank Miette Stuyck for excellent technical assistance, A.
Chimirri (University of Messina, Messina, Italy) for synthesizing
TBZE-029, and G. Pürstinger (University of Innsbruck, Innsbruck,
Austria) for the synthesis of enviroxime.

REFERENCES

1. Aldabe, R., A. Barco, and L. Carrasco, 1996. Membrane permeabilization by
and B. A. Heinz, 1999. Evidence that enviroxime targets multiple compo-
5. Cousin, J., 2006. Report concludes polo drugs are needed—after disease is